A one-step platform for screening high-efficient and minimal off-target CRISPR/Cas13 crRNAs to eradicate SARS-CoV-2 virus for treatment of COVID-19 patients

Li, Pu‐Yu; Li, Sanqiang; Gao, Shegan; Dong, Daoyin

doi:10.1016/j.mehy.2021.110754

Cited by 5 publications

(2 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results clearly illustrate the function of the CRISPR technique in the detection of the RdRp of SARS-CoV-2. However, it is still challenging to demonstrate the treatment function [ 140 ]. It is worth further exploring its therapeutic potential.…”

Section: Crispr Cas Technologymentioning

confidence: 99%

Newly Emerged Antiviral Strategies for SARS-CoV-2: From Deciphering Viral Protein Structural Function to the Development of Vaccines, Antibodies, and Small Molecules

Zhang

Yang

2022

IJMS

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) caused by the infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become the most severe health crisis, causing extraordinary economic disruption worldwide. SARS-CoV-2 is a single-stranded RNA-enveloped virus. The process of viral replication and particle packaging is finished in host cells. Viral proteins, including both structural and nonstructural proteins, play important roles in the viral life cycle, which also provides the targets of treatment. Therefore, a better understanding of the structural function of virus proteins is crucial to speed up the development of vaccines and therapeutic strategies. Currently, the structure and function of proteins encoded by the SARS-CoV-2 genome are reviewed by several studies. However, most of them are based on the analysis of SARS-CoV-1 particles, lacking a systematic review update for SARS-CoV-2. Here, we specifically focus on the structure and function of proteins encoded by SARS-CoV-2. Viral proteins that contribute to COVID-19 infection and disease pathogenesis are reviewed according to the most recent research findings. The structure-function correlation of viral proteins provides a fundamental rationale for vaccine development and targeted therapy. Then, current antiviral vaccines are updated, such as inactive viral vaccines and protein-based vaccines and DNA, mRNA, and circular RNA vaccines. A summary of other therapeutic options is also reviewed, including monoclonal antibodies such as a cross-neutralizer antibody, a constructed cobinding antibody, a dual functional monoclonal antibody, an antibody cocktail, and an engineered bispecific antibody, as well as peptide-based inhibitors, chemical compounds, and clustered regularly interspaced short palindromic repeats (CRISPR) exploration. Overall, viral proteins and their functions provide the basis for targeted therapy and vaccine development.

show abstract

Section: Crispr Cas Technologymentioning

confidence: 99%

Newly Emerged Antiviral Strategies for SARS-CoV-2: From Deciphering Viral Protein Structural Function to the Development of Vaccines, Antibodies, and Small Molecules

Zhang

Yang

2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Gootenberg et al designed a fast, cheap, and sensitive portable nucleic acid diagnosis platform, called SHERLOCK, based on the RNA trans-cleavage activity of Cas13 type VI CRISPR systems and strict crRNA complementary base pairing, and successfully applied it for nucleic acid detection and diagnosis [ 97 ]. Later, it was gradually applied to the studies of COVID-19, cancer mutations, and plant genetic traits improvement [ 48 , 51 , 52 , 53 ]. Currently, researchers are conducting a large-scale clinical study to evaluate SHERLOCK’s availability as a cheap and reliable diagnostic tool for COVID-19 [ 98 , 99 ].…”

Section: Application and Prospect Of Cas13 In Type VI Crispr Systemsmentioning

confidence: 99%

Insights Gained from RNA Editing Targeted by the CRISPR-Cas13 Family

Liu

Pei

2022

IJMS

View full text Add to dashboard Cite

Clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated protein (Cas) systems, especially type II (Cas9) systems, have been widely developed for DNA targeting and formed a set of mature precision gene-editing systems. However, the basic research and application of the CRISPR-Cas system in RNA is still in its early stages. Recently, the discovery of the CRISPR-Cas13 type VI system has provided the possibility for the expansion of RNA targeting technology, which has broad application prospects. Most type VI Cas13 effectors have dinuclease activity that catalyzes pre-crRNA into mature crRNA and produces strong RNA cleavage activity. Cas13 can specifically recognize targeted RNA fragments to activate the Cas13/crRNA complex for collateral cleavage activity. To date, the Cas13X protein is the smallest effector of the Cas13 family, with 775 amino acids, which is a promising platform for RNA targeting due to its lack of protospacer flanking sequence (PFS) restrictions, ease of packaging, and absence of permanent damage. This study highlighted the latest progress in RNA editing targeted by the CRISPR-Cas13 family, and discussed the application of Cas13 in basic research, nucleic acid diagnosis, nucleic acid tracking, and genetic disease treatment. Furthermore, we clarified the structure of the Cas13 protein family and their molecular mechanism, and proposed a future vision of RNA editing targeted by the CRISPR-Cas13 family.

show abstract